Nachrichten zur Johnson & Johnson Aktie

Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week

…

3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond

Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend…

This Vanguard ETF Has 23% of Its Portfolio Invested in Tech Stocks, but It Can Still Help You Generate Decades of Passive Income

The technology sector has crushed the S&P 500 over the past three, five, and 10 years as leading tech stocks…

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care…

Johnson & Johnsons AAA rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition By Investing.com

Johnson & Johnsons AAA rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition…

AIM movers: Trellus Health partners with Johnson & Johnson and Thruvision strategic review

Digital healthcare platform developer Trellus Health (LON: TRLS) has entered an agreement with Johnson & Johnson Health Care Systems Inc…

Johnson & Johnson setzt mit 14,6 Mrd. USD schwerem Intra-Cellular-Deal auf Medikamente für psychische Erkrankungen

Johnson & Johnson hat eine Vereinbarung zur Übernahme aller ausstehenden Aktien von Intra-Cellular Therapies geschlossen, eine Multimilliarden-Dollar-Wette auf Therapien für…

Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

…

Johnson & Johnson kündigt Übernahme von Intra-Cellular Therapies an.

WerbungFür rund 14,6 Milliarden US-Dollar kauft das Pharmaunternehmen den Arzneimittelhersteller.Wie am Montag bekannt gegeben wurde, wird das Pharmaunternehmen Johnson &…

Milliarden-Deal! Johnson & Johnson schluckt AKTIONÄR-Tipp Intra-Cellular – satte Prämie

Die diesjährige JPMorgan Healthcare Conference beginnt mit einem Paukenschlag: Johnson & Johnson will sich im Bereich der Neurowissenschaften verstärken und…

Milliarden-Deal! Johnson & Johnson schluckt AKTIONÄR-Tipp Intra-Cellular – satte Prämie

Die diesjährige JPMorgan Healthcare Conference beginnt mit einem Paukenschlag: Johnson & Johnson will sich im Bereich der Neurowissenschaften verstärken und…

Pharmaindustrie: Johnson & Johnson übernimmt Intra-Cellular Therapies für 14,6 Milliarden Dollar

Die Übernahme gibt dem Johnson & Johnson Zugang zu einem in den Vereinigten Staaten stark nachgefragten Medikament. Damit stärkt der…

Johnson & Johnson mit Milliardenübernahme von Intra-Cellular - Intra-Cellular-Aktie +35 Prozent

Je Aktie legt J&J dafür 132 US-Dollar auf den Tisch und bezahlt damit insgesamt 14,6 Milliarden Dollar (14,2 Mrd Euro),…

ROUNDUP: Johnson & Johnson übernimmt Intra-Cellular für Milliardensumme

NEW BRUNSWICK/BEDMINSTER (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) stärkt sich mit dem Zukauf der Biopharma-Firma…

ROUNDUP: Johnson & Johnson übernimmt Intra-Cellular für Milliardensumme

NEW BRUNSWICK/BEDMINSTER (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) stärkt sich mit…

J&J to buy Intra-Cellular Therapies for $14.6 billion

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in…

2 Beaten-Down Dividend Stocks to Buy in 2025

Dividend stocks are great for various reasons, and its even better to invest in them while they are going through…

9 Dividend ETFs to Buy With $200 and Hold Forever

Savvy investors know that dividends are powerful wealth builders -- and not, as many assume, sleepy, safe stocks for your…

Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies

Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the…

Kreise: Johnson & Johnson in Gesprächen zu Intra-Cellular-Übernahme

NEW YORK (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) ist Kreisen zufolge…

Kreise: Johnson & Johnson in Gesprächen zu Intra-Cellular-Übernahme

NEW YORK (dpa-AFX) - Der US-Pharma- und Medizintechnikkonzern Johnson & Johnson (J&J) ist Kreisen zufolge an einer Übernahme der…

Johnson & Johnson in talks to acquire Intra-Cellular - Bloomberg

…

Meet the 15 Dow Jones Stocks That Combined for Over $150 Billion in Dividends in 2024 and Will All Likely Boost Their Payouts Again in 2025

The Dow Jones Industrial Average (DJINDICES: ^DJI) is composed of 30 industry-leading blue-chip businesses that represent the broader market. Many…

Johnson & Johnson Aktie: Schlüsselakteur im MedTech-Sektor

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein: Sanford C. Bernstein hat das Kursziel für die Aktie von…

Johnson & Johnson stock sinks on Varipulse concerns By Investing.com

Johnson & Johnson stock sinks on Varipulse concerns…

Johnson & Johnson: A Potential Beneficiary Of A Great Rotation

…

Johnson & Johnson: Im Saying Yes To This Mess

…

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a…

J&J lung cancer treatment extends lives versus AstraZeneca drug

Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients’ lives compared to AstraZeneca PLC (LSE:AZN)’s...…

Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson

Todays Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and…

Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F. Hoffmann-La Roche, Johnson & Johnson, and AstraZeneca

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough…

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Johnson & Johnson announces a global licensing deal with Kaken for the latters eczema candidate, KP-723, to further strengthen its…

The Smartest Dividend Stocks to Buy With $1,000 Right Now

If youre looking for attractive dividend-paying stocks, thats a smart move. If youre not, perhaps reconsider -- because: Healthy and growing…

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what…

Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks

Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you…

1 Vanguard Index Fund Could Turn $375 Per Month Into a $569,400 Portfolio That Pays $17,200 in Annual Dividend Income

The median weekly income for U.S. workers was $1,165 in the third quarter, which is roughly $60,500 per year, according…

Worried About a Stock Market Sell-Off in 2025? Consider Buying This Ultra-Safe Vanguard ETF in December.

Volatility spiked in the broader indexes after the Federal Reserve indicated that it could keep interest rates higher for longer.…

A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now

Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index…

Analyst Report: Johnson Controls Intl pl

…

Johnson & Johnson: Dividend Legend At A Discount

…

What Really Matters

At the time of year where everyone is reflecting on the things that matter most to them in their personal…

The Smartest Dividend Stocks to Buy With $500 Right Now

As an investor, your goal is to select quality stocks that will advance over a period of years -- but…

Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout

Dividend investors often prioritize stocks that have long track records for raising their payouts. But that can be a mistake.…

Shoe Deodorizers: Global Market Analysis, Key Competitors by Region, Annual Sales Data Since 2014, Industry Shares and Revenue Forecasts to 2030

The Top 10 Players Dominating Revenues are Reckitt Benckiser Group PLC, S.C. Johnson & Son, Inc., Church & Dwight Co.…

dpa-AFX ProFeed